Olmesartan Medoxomilo + Hidroclorotiazida Ciclum (Olmesartan Medoxomil, Hydrochlorothiazide)

Olmesartan medoxil selectively blocks AT‑1 receptors for angiotensin II, preventing vasoconstriction and aldosterone‑mediated sodium retention. Hydrochlorothiazide acts on the distal convoluted tubule to inhibit sodium‑chloride reabsorption, increasing urine output. Together they lower peripheral resistance and plasma volume, producing a sustained reduction in arterial pressure.

The appropriate dose of Olmesartan Medoxomilo + Hidroclorotiazida Ciclum is determined by the prescribing clinician based on the patient’s blood pressure, renal function, and response to therapy. Dosage adjustments are made according to clinical guidelines and individual patient needs.

Olmesartan medoxil is contraindicated in pregnancy, particularly in the second and third trimesters, because it can cause fetal toxicity. Hydrochlorothiazide is also generally avoided during pregnancy. Breastfeeding mothers should consult their healthcare provider, as the drugs may pass into breast milk and affect the infant.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifying trade or institutional credentials before providing pricing, availability, shipping details, and any necessary import documentation.

Compared with monotherapy using either an ARB or a thiazide alone, the olmesartan‑hydrochlorothiazide combo offers synergistic blood‑pressure reduction, often achieving target levels with a single pill. It may be preferred over ACE‑inhibitor‑diuretic combos for patients who experience cough with ACE inhibitors, while providing similar efficacy to other ARB‑diuretic combinations.

Store the tablets at temperatures below 25 °C in their original container, protecting them from moisture, heat, and direct sunlight. Do not refrigerate or freeze the product, and keep it out of reach of children.

The medication is taken orally, usually once daily, with or without food, as directed by the prescribing clinician. Swallow the tablet whole with a glass of water; do not crush or chew it unless specifically instructed.

Serious adverse events, though uncommon, include severe hypotension, acute kidney injury, hyperkalemia, angio‑edema, and liver enzyme elevations. Patients should seek immediate medical attention if they experience swelling of the face or throat, sudden dizziness, or marked decreases in urine output.

The combination should be avoided in patients with known hypersensitivity to olmesartan, hydrochlorothiazide, or any excipients, as well as in pregnant women (second and third trimesters) and those with severe renal impairment, hyperkalemia, or anuria. Clinicians should also exercise caution in patients with a history of gout or hepatic disease.